Product Description
An orally bioavailable, adenosine triphospate mimetic, and inhibitor of Aurora kinases, vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor (PDGFRs), with potential antineoplastic activity. Upon administration, ilorasertib selectively binds to and inhibits Aurora kinases A, B and C, which may disrupt both the assembly of the mitotic spindle apparatus and chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. In addition, ilorasertib selectively binds to and inhibits VEGFRs and PDGFRs, which may result in the inhibition of both angiogenesis and tumor cell proliferation in VEGFR/PDGFR-overexpressing tumor cells. This agent also inhibits the Src family of cytoplasmic tyrosine kinases. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs are receptor tyrosine kinase families whose members may be upregulated in various tumor cell types. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ilorasertib)
Mechanisms of Action: AURK Inhibitor,VEGF Inhibitor,PGFR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Bone Cancer|Pregnancy Outcomes|Mouth Cancer
Phase 1: Chronic Myeloid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCI-2015-01251 | P2 |
Terminated |
Mouth Cancer|Pregnancy Outcomes|Bone Cancer |
2022-05-12 |
|
IRB15-0083 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2019-02-08 |
|
M10-944 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-09-01 |
|
M10-943 | P1 |
Completed |
Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Preleukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2013-06-01 |